Neoadjuvant immunochemotherapy using intratumoral injection of dendritic cells for thoracic esophageal cancers

Neoadjuvant immunochemotherapy using intratumoral injection of dendritic cells for thoracic esophageal cancers - Neoadjuvant immunochemotherapy using intratumoral injection of dendritic cells for thoracic esophageal cancers

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000669

Enrollment

Registered

2007-09-01

Start date

2007-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracic esophageal cancers

Interventions

intratumoral injection of dendritic cells on day 3 in the 1st course of neoadjuvant chemotherapy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients are diagnosed as having lymph node metastasis using CT scan and PET scan. Patients have not received any other treatent for esophageal cancers.

Exclusion criteria

Exclusion criteria: Patients with serious concomitant disease Patients with autoimmune disease

Design outcomes

Primary

Measure	Time frame
Incidence of adverse event	—

Countries

Japan

Contacts

Public ContactHiroshi Miyata

Graduate School of Medicine, Osaka University Department of Gastroenterological Surgery

hmiyata@gesurg.med.osaka-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026